SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Citi’s 11th Annual Biotech Conference September 7 in Boston
Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology September 28 in New York
SAN RAFAEL, Calif., Aug. 31, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that management will participate in the Gene Therapy Panel at Citi’s 11th Annual Biotech Conference on September 7, 2016 at 1:00pm ET in Boston, the Robert W. Baird & Co. 2016 Global Healthcare Conference September 8, 2016 at 9:40am ET in New York and the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on September 28, 2016 at 10:00am ET in New York. To access the live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
